latest updates in the global new drug development field, including progress in new drug research and development.

Avidity Biosciences begins a biomarker group in the FORTITUDE™ trial to seek potential fast-track approval for Delpacibart Braxlosiran (del-brax/AOC 1020).

10.28-11.3, Global Pharmaceutical Investment, Financing and Deal Events Summary.

Akeso has initiated patient recruitment for a Phase 3 study assessing Ivonescimab alongside Ligufalimab (CD47) as a first-line therapy for HNSCC.

BMS-986408 is a small molecule drug developed by Bristol-Myers Squibb Pharmaceuticals Ltd.

HLX14, a biosimilar candidate for PROLIA/XGEVA (denosumab), has been accepted by the US Food and Drug Administration (FDA).

we will use the drug Amisulpride as an example to demonstrate how to quickly obtain information about its chemical structure and patent situation using the Patsnap Chemical.

BridgeBio Oncology Therapeutics (BBOT) reports that the first patient has been treated with BBO-10203, a novel RAS:PI3Kα inhibitor.

Nedosiran, also known by its brand name RIVFLOZA, is an innovative RNA interference (RNAi) therapeutic developed by Dicerna Pharmaceuticals.

Three Phase 3 studies have begun using Datopotamab Deruxtecan combinations in patients with advanced nonsquamous non-small cell lung cancer.

Apixaban is a small molecule drug that targets factor Xa and has been approved for the treatment of various therapeutic areas.

Alterome Therapeutics has dosed the first patient in its Phase 1 trial of ALTA2618 for AKT1 E17K-mutant solid tumors (AKTive-001).